Walsh Kathleen E 4

What Happened

• Kathleen E. Walsh, a director of Beam Therapeutics (BEAM), was granted 19,676 derivative share awards on 2026-06-03. The filing reports an acquisition price of $0.00 (no cash paid) for the award. This was a grant/award (not a market purchase or sale) and no shares were sold.

Key Details

• Transaction date: 2026-06-03; Form 4 filed: 2026-06-05 (timely filing).
• Transaction type/code: Grant/Award (A); amount: 19,676 shares; reported price: $0.00.
• Shares owned after transaction: Not specified in the filing.
• Footnote: The award vests in full on the earlier of the first anniversary of the grant date and immediately prior to the next year's annual meeting, conditioned on continued service to the board.
• No 10b5-1 plan, tax‑withholding sale, or cashless exercise reported.

Context

• This is a compensation grant to a director (a common, non‑market transaction) and reflects equity-based pay rather than a personal buy or sell. Because it is a time‑vested derivative award, the economic benefit depends on future vesting and any subsequent exercise or settlement.